Accuray Q4 Loss Narrows; Issues FY14 Revenue Outlook - Quick Facts

(RTTNews) - Accuray Inc. (ARAY), a radiation oncology company, reported a fourth-quarter net loss attributable to stockholders of $18.7 million or $0.25 per share, narrower than $20.3 million or $0.28 per share in the comparable quarter last year.

Excluding items, non-GAAP net loss attributable to shareholders for the quarter was $15.1 million, wider than $14.2 million in the year-ago period. Loss per share for the latest fourth quarter was $0.20, same as last year.

On average, six analysts polled by Thomson Reuters expected the company to lose $0.20 per share for the quarter. Analysts' estimates typically exclude special items.

Total net revenue for the latest quarter rose to $84.90 million from $100.53 million last year, while five analysts had a consensus revenue estimate of $82.29 million for the quarter.

For the full fiscal year 2014, Accuray expects that revenue will be in the range of $325 million to $345 million. Analysts currently expect revenues of $351.54 million for the full fiscal year 2014.